Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetazolamide/Dronabinol - Incannex Healthcare

Next Previous
Drug Profile

Acetazolamide/Dronabinol - Incannex Healthcare

Alternative Names: IHL-42X

Latest Information Update: 06 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incannex Healthcare
  • Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Sleep disorder therapies; Small molecules; Thiadiazoles; Thiazoles
  • Mechanism of Action Cannabinoid CB1 receptor agonists; Cannabinoid receptor CB2 agonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Sleep apnoea syndrome

Most Recent Events

  • 27 Jul 2026 Incannex Healthcare completes a phase II/III trial in in Sleep apnoea syndrome (Treatment-naive) in USA (PO) (NCT06146101)
  • 21 Jul 2026 Incannex Healthcare initiates enrolment in the phase II DReAMzz trial for Sleep-apnoea-syndrome in USA (NCT07635563)
  • 09 Jun 2026 Incannex Healthcare plans a phase II trial for Obstructive Sleep Apnea in China, in June 2026 (NCT07635563)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top